In parallel, exploring the therapeutic potential of modulating mitophagy pathways, for example, by using pharmacological agents to activate or inhibit BNIP3L, may help determine whether targeting mitophagy can effectively reduce adipose tissue inflammation and improve metabolic outcomes in obesity. The gene discussed is BNIP3L; the disease is obesity due to melanocortin 4 receptor deficiency.